| [1] | Frisoni G B., Hansson O., Nichols E., et al. (2025). New landscape of the diagnosis of Alzheimer’s disease. Lancet 406:1389−1407. DOI:10.1016/S0140-6736(25)01294-2 |
| [2] | Villemagne V L., Burnham S., Bourgeat P., et al. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 12:357−367. DOI:10.1016/S1474-4422(13)70044-9 |
| [3] | Joling K J., Janssen O., Francke A L., et al. (2020). Time from diagnosis to institutionalization and death in people with dementia. Alzheimers Dement. 16:662−671. DOI:10.1002/alz.12063 |
| [4] | Phillips B., Sanford J., Janve V A., et al. (2026). Blood-based circular RNAs for early diagnosis of Alzheimer’s disease. Nat. Med. DOI:10.1038/s41591-026-04485-5 |
| [5] | 2026). Early detection of Alzheimer’s disease with circular RNA from blood. Nat. Med. 32: 2745–2746. DOI:10.1038/s41591-026-04563-8 |
| Chen L., Sun F., Xi E., et al. (2026). Blood-based circular RNAs emerge as a breakthrough early diagnostic tool for Alzheimer’s disease. The Innovation Neurology 1:100003. https://doi.org/10.59717/j.xinn-tine.2026.100003 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Schematic illustrations of the Blood-Based Circular RNAs acted as an Early Diagnostic Tool for Alzheimer’ s Disease.